Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise



Status:Recruiting
Conditions:Diabetes, Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - Any
Updated:12/12/2018
Start Date:December 5, 2017
End Date:August 2020
Contact:Trial Transparency email recommended (Toll free number for US & Canada)
Email:Contact-Us@sanofi.com
Phone:800-633-1610

Use our guide to learn which trials are right for you!

A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

Primary Objective:

To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to
placebo in glycated hemoglobin (HbA1c) change in participants with T2DM (Type 2 Diabetes
Mellitus) inadequately controlled with diet and exercise.

Secondary Objectives:

- To demonstrate the superiority of once-weekly injection of efpeglenatide in comparison
to placebo on glycemic control

- To demonstrate the superiority of once-weekly injection of efpeglenatide in comparison
to placebo on body weight

- To evaluate the safety of once-weekly injection of efpeglenatide

Study duration per participant is approximately 65 weeks, including a 3-week screening
period, 30 weeks core treatment period, 26 weeks extension treatment period, and 6 weeks
safety follow up.

Inclusion criteria:

- Participants must be at least 18 years of age at the time of signing the informed
consent.

- Participants with T2DM, and treated with diet and exercise.

- Hemoglobin A1c between 7.0% and 10.0% (inclusive) measured by the central laboratory
at Screening.

Exclusion criteria:

- Clinically relevant history of gastrointestinal disease associated with prolonged
nausea and vomiting, including (but not limited to) gastroparesis, unstable and not
controlled gastroesophageal reflux disease within 6 months prior to Screening or
history of surgery affecting gastric emptying.

- History of pancreatitis (unless pancreatitis was related to gallstone and
cholecystectomy has been performed) and pancreatitis during previous treatment with
incretin therapies, chronic pancreatitis, and pancreatectomy.

- Personal or family history of Medullary Thyroidian Cancer (MTC) or genetic conditions
that predisposes to MTC (eg multiple endocrine neoplasia syndromes).

- Retinopathy or maculopathy with one of the following treatments, either recent (within
3 months of screening) or planned: intravitreal injections or laser or vitrectomy
surgery.

- Body weight change of ≥5 kg within the last 3 months prior to Screening.

- Systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg at
Randomization.

- End-stage renal disease as defined by estimated glomerular filtration rate (eGFR , by
Modification of Diet in Renal Disease [MDRD]) of <15 mL/min/1.73 m2.

- Laboratory findings at the Screening Visit:

- Alanine aminotransferase (ALT ) or aspartate aminotransferase (AST ) >3 times the
upper limit of the normal (ULN ) or total bilirubin >1.5 times the ULN (except in case
of documented Gilbert's syndrome).

- Amylase and/or lipase: >3 times the ULN laboratory range.

- Calcitonin ≥5.9 pmol/L (20 pg/mL).

- Gastric surgery or other gastric procedures intended for weight loss within 2 years
prior to Screening, or planned during study period.

- History of drug or alcohol abuse within 6 months prior to the time of Screening.

- Pregnant (demonstrated by serum pregnancy test at Screening) or breast-feeding women.

- Women of childbearing potential not willing to use highly effective method(s) of birth
control during the study period and for at least 5 weeks after the last dose of study
intervention.

The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.
We found this trial at
30
sites
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Berlin,
Click here to add this to my saved trials
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
?
mi
from
Bridgeton, NJ
Click here to add this to my saved trials
Burlington, North Carolina 27215
?
mi
from
Burlington, NC
Click here to add this to my saved trials
?
mi
from
Canoga Park, CA
Click here to add this to my saved trials
?
mi
from
Carrollton, TX
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Chula Vista, CA
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
DeLand, FL
Click here to add this to my saved trials
?
mi
from
Glendale, AZ
Click here to add this to my saved trials
?
mi
from
Hatboro, PA
Click here to add this to my saved trials
?
mi
from
Hialeah, FL
Click here to add this to my saved trials
?
mi
from
Holladay, UT
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
?
mi
from
La Mesa, CA
Click here to add this to my saved trials
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
?
mi
from
Maumee, OH
Click here to add this to my saved trials
?
mi
from
Plano, TX
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
Schertz, TX
Click here to add this to my saved trials
?
mi
from
Snellville, GA
Click here to add this to my saved trials
?
mi
from
Tarzana, CA
Click here to add this to my saved trials
?
mi
from
Upland, CA
Click here to add this to my saved trials
?
mi
from
Van Nuys, CA
Click here to add this to my saved trials
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Wilmington, North Carolina 28401
?
mi
from
Wilmington, NC
Click here to add this to my saved trials